Authors of COVID-19 Study Retract Their Findings On Effects Of Trump Administration Backed Hydroxychloroquine

In this photo illustration, a box and tablets on a blister pack of Plaquinol (Hydroxychloroquine) are displayed
Buda Mendes / Getty Images

The majority of the authors of a high-profile study done on the effects of hydroxychloroquine, the controversial anti-malaria drug used in the treatment of COVID-19, have retracted their previous findings that the drug puts patients at a higher risk.

The authors of the trial, led by Mandeep R. Mehra of Harvard Medical School, published it in late May in The Lancet Journal of Medicine. Three of the four authors have now retracted their study after an independent peer review wasn’t allowed access to the data that was used by the researchers, according to The Hill.

The publication reported that the data for the study was obtained from the Surgisphere Corporation, which told the reviewers that they would not be allowed access to the entire dataset in order to study it. The corporation cited that allowing access would violate the confidentiality agreement that it has with clients. The Surgisphere Corporation is owned by Sapan Desai, one of the co-authors of the study. Desai did not sign onto the retraction by the other authors.

Three of the four authors released a statement on Thursday saying that they “entered this collaboration to contribute in good faith and at a time of great need during the COVID-19 pandemic.”

“We deeply apologize to you, the editors, and the journal readership for any embarrassment or inconvenience that this may have caused.”

The medical journal that released the study also issued a statement declaring that it “takes issues of scientific integrity extremely seriously” and that it believes there are “many outstanding questions about Surgisphere and the data that were allegedly included in this study,” according to The Hill.

The publication reported that the study claimed to have looked at the results of 96,000 COVID-19 patients who were being treated in 671 hospitals on six different continents.

U.S. President Donald Trump began to support the use of hydroxychloroquine early in the COVID-19 pandemic crackdown. Just weeks ago, the president announced that he has been taking the drug, which was disavowed by doctors after it became a topic in the news.

As The Inquisitr previously reported, the president’s announcement that he has been taking hydroxychloroquine prophylactically was followed just days later by the announcement that he would soon stop taking the drug.

The president stated that he was taking the drug with zinc and that his White House doctor signed off on him taking the malaria treatment. The doctor told the press of Trump’s use of the drug that “the potential benefit from treatment outweighed the relative risks.”